Amin Haghighat Jahromi

Dr. Amin Haghighat Jahromi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2020 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
AJAmin Haghighat Jahromi
Amin Haghighat Jahromi
DBDonald A. Barkauskas
Donald A. Barkauskas
MZMatthew Zabel
Matthew Zabel
AGAaron M. Goodman
Aaron M. Goodman
GFGarret Frampton
Garret Frampton
RKRazelle Kurzrock
Razelle Kurzrock
Purpose: Deriving links between imaging and genomic markers is an evolving field. 2-[18F]FDG PET/CT (18F-fluorodeoxyglucose positron emission tomography–computed tomography) is commonly used for cancer imaging, with maximum standardized uptake value (SUVmax) as the main quantitative parameter. Tumor mutational burden (TMB), the quantitative variable obtained using next-generation sequencing on a tissue biopsy sample, is a putative immunotherapy response predictor. We report the relationship between TMB and SUVmax, linking these two important parameters. Methods: In this pilot study, we analyzed 1923 patients with diverse cancers and available TMB values. Overall, 273 patients met our eligibility criteria in that they had no systemic treatment prior to imaging/biopsy, and also had 2-[18F]FDG PET/CT within 6 months prior to the tissue biopsy, to ensure acceptable temporal correlation between imaging and genomic evaluation. Results: We found a linear correlation between TMB and SUVmax (p < 0.001). In the multivariate analysis, only TMB independently correlated with SUVmax, whereas age, gender, and tumor organ did not. Conclusion: Our observations link SUVmax in readily available, routinely used, and noninvasive 2-[18F]FDG PET/CT imaging to the TMB, which requires a tissue biopsy and time to process. Since higher TMB has been implicated as a prognostic biomarker for better outcomes after immunotherapy, further investigation will be needed to determine if SUVmax can stratify patient response to immunotherapy.

27 May 2022 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
SBSudhir Md Bhimaniya
Sudhir Md Bhimaniya
AJAmin Haghighat Jahromi
Amin Haghighat Jahromi
Newly diagnosed low-grade bilateral breast lymphoma in 63-year-old woman demonstrated intense FDG uptake in the left axillary lymph nodes and the spleen, concerning for lymphomatous involvement. Subsequent ultrasound-guided biopsy did not demonstrate any pathologic left axillary lymph nodes. Further investigation revealed COVID-19 vaccination in the left arm, 5 days prior to the 18F-FDG PET/CT study. Six-month follow-up 18F-FDG PET/CT showed resolution of the intense FDG uptake in the left axillary lymph nodes and spleen without any treatment, suggesting a self-remitting acute local and systemic immune response to COVID-19 vaccination.

1 January 2021
Verified
Journal Article
Closed access
AJAmin Haghighat Jahromi
Amin Haghighat Jahromi
MZMatthew Zabel
Matthew Zabel
RORyosuke Okamura
Ryosuke Okamura
CHCarl K. Hoh
Carl K. Hoh
RKRazelle Kurzrock
Razelle Kurzrock

15 April 2021 in BMC Medical Imaging
Verified
Journal Article
Open access
PDF file
AJAmin Haghighat Jahromi
Amin Haghighat Jahromi
AGAaron M. Goodman
Aaron M. Goodman
CHCarl K. Hoh
Carl K. Hoh
Background: Rosai-Dorfman-Destombes (RDD) disease, is a rare proliferative and inflammatory disorder of non-Langerhans cell histiocytes. Case presentation: We report a 35-year-old woman, who originally presented with recurrent episodes of lower extremity joint/bone pain and chronic nasal stuffiness and congestion. Her worsening nasal congestion was due to an obstructing nasal cavity lesion which was subsequently biopsied. Pathology was consistent with RDD. 18F-FDG PET images demonstrated intense uptake in the paranasal sinuses and a large pelvic lymph node. Focal osseous lesions with intense 18F-FDG uptake were also observed in the lower extremity, corresponding to areas of peri-articular pain. Rheumatologic work-up was consistent with palindromic rheumatism. She was diagnosed with immune-related disseminated RDD, presenting as palindromic rheumatism. Conclusions: This is the first case of RDD presenting as palindromic rheumatism. RDD should be considered as a possible but rare diagnosis in young patients with sinus-related symptoms and lymphadenopathy. The disease can on rare occasions be disseminated and can also present as immune-related RDD, such as in this patient.

31 May 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
AJAmin Haghighat Jahromi
Amin Haghighat Jahromi
WJWilliam F. James
William F. James
MSMichael D. Starsiak
Michael D. Starsiak
ESEugene D. Silverman
Eugene D. Silverman
This paper details the case report of a 26-year-old man who presented with a growing right-sided skull mass evaluated with ultrasound, non-contrast CT, contrast-enhanced MRI and 99mTc-MDP whole body bone scan with SPECT/CT. These studies suggested a broad differential diagnosis favoring benign osseous lesions. Given a more recent increase in the rate of growth, headache and large size, the lesion was excised via craniotomy followed by cranioplasty. Pathology confirmed fibrous dysplasia (FD) as the diagnosis. Interestingly, this report is the imaging evaluation of the exophytic subtype of FD, the so-called FD protuberance, an extremely rare variant of FD, of which only two case reports are found in the literature.

1 November 2020 in Cancer Biology & Therapy
Verified
Journal Article
Open access
AJAmin Haghighat Jahromi
Amin Haghighat Jahromi
GCGeraldine Chang
Geraldine Chang
RKRazelle Kurzrock
Razelle Kurzrock
CHCarl K. Hoh
Carl K. Hoh
Cancer diagnosis and therapy is quickly moving from the traditional histology-based approaches to genomic stratification, providing a huge opportunity for radiogenomics, associating imaging features with genomic data. Genome sequencing is time consuming, expensive and invasive whereas 18F-FDG PET/CT is readily available, fast and noninvasive. The aim of this study was to determine the relationship between the maximum standardized uptake value (SUVmax) and the frequency of 11 common oncogenic anomalies determined by specific common genomic alterations in tissue biopsies from patients with cancer. We retrospectively studied 102 consecutive untreated patients with gastrointestinal, lung, and breast cancer who underwent 18F-FDG PET/CT imaging, shortly prior to molecular testing by a biopsy for genomic profiling that consisted of 11 common DNA alterations: (1) TP53, (2) DNA repair, (3) EGFR, (4) PI3K/AKT/MTOR (PAM) pathway including PTEN, PIK3CA, AKT, TSC, CCNB1, MTOR, FBXW2, and NF2, (5) MEK, (6) CYCLIN including CCND,CDK, CDKN, and RB, (7) WNT, (8) ALK, (9) MYC, (10) MET, and (11) FGF/FGFR. Higher SUVmax was associated with the presence of TP53 and PAM genomic anomalies (p < .05), but not the other 9 gene groups (p > .05). More importantly, SUVmax was positively correlated with total number of oncogenic anomalies (r = 0.27, p = .005). We propose higher SUVmax as an indicator for total number of common oncogenic anomalies. This finding is a step forward in noninvasive stratification of cancer patients, in terms of the overall load of oncogenic anomalies, based on their SUVmax.